Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 5 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready • 14 patents granted in the last 365 days
Xiamen University has 7 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are spread across 7 distinct examiners and 5 distinct art units. NOA WILLIAM FRAN GROOMS is the busiest examiner, responsible for 1 pending office action.
The distribution of 7 pending office actions among 7 distinct examiners means that every active matter is being reviewed by a different individual. This variety is further reflected in the 5 distinct art units involved. NOA WILLIAM FRAN GROOMS handles 1 pending office action, which is the same workload as every other examiner in the portfolio. Practitioners should be prepared for 7 different examiner perspectives within the Biotechnology & Pharmaceuticals sector.
The presence of 5 distinct art units suggests that the university's research covers a wide range of sub-specialties. This decentralized structure requires a flexible prosecution strategy to address the unique requirements of 7 different examiners across multiple art units. With 5 distinct art units for 7 pending office actions, there is very little overlap in the administrative or technical oversight of the portfolio, requiring individualized attention for each application.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 3 (43%) |
| §112 only | 2 (29%) |
| Multi-statute (no §101) | 2 (29%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GROOMS, NOA WILLIAM FRAN | 1 | 75.0% | +0.0% |
| WANG, RUIXUE | 1 | 57.4% | +17.8% |
| VARADARAJ, ARCHANA | 1 | 80.0% | +33.3% |
| AULAKH, CHARANJIT | 1 | 80.6% | -14.5% |
| NIEBAUER, RONALD T | 1 | 40.8% | +34.0% |
| REYNOLDS, FRED H | 1 | 33.0% | +39.2% |
| JAUHARI, SACHI | 1 | 60.0% | +80.0% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18544186 | CATALYST, APPLICATION THEREOF, AND METHOD FOR PREPARING 2,5-FURANEDICARBOXYLIC ACID BY CATALYZING 5-HYDROMETHYLFURFURAL IN BASE-FREE CONDITION | AULAKH, CHARANJIT | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18350803 | PEPTIDE DISINFECTANT FOR PREVENTING CORONAVIRUSES | NIEBAUER, RONALD T | 60d |
| 18704949 | LUMINESCENT MATERIAL AND MINI-LED DEVICE PREPARED USING LUMINESCENT MATERIAL | GROOMS, NOA WILLIAM FRAN | — |
| 18292538 | GENERAL AFFINITY EPITOPE POLYPEPTIDE FOR HUMAN RHINOVIRUS, AND ANTIBODY AND USES THEREOF | WANG, RUIXUE | — |
| 18398278 | ANTIMICROBIAL PEPTIDE SCYAMPCIN44-63 AND APPLICATION THEREOF | VARADARAJ, ARCHANA | — |
| 18005543 | CELL-PENETRATING PEPTIDE AND USE THEREOF | JAUHARI, SACHI | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18350803 | PEPTIDE DISINFECTANT FOR PREVENTING CORONAVIRUSES | NIEBAUER, RONALD T | 60d |
| 18337091 | PREPAKAGED POLYMERASE CHAIN REACTION (PCR) REAGENT FOR NUCLEIC ACID AMPLIFICATION AND METHOD THEREOF | REYNOLDS, FRED H | 70d |
| 18292538 | GENERAL AFFINITY EPITOPE POLYPEPTIDE FOR HUMAN RHINOVIRUS, AND ANTIBODY AND USES THEREOF | WANG, RUIXUE | — |
| 18398278 | ANTIMICROBIAL PEPTIDE SCYAMPCIN44-63 AND APPLICATION THEREOF | VARADARAJ, ARCHANA | — |
| 18005543 | CELL-PENETRATING PEPTIDE AND USE THEREOF | JAUHARI, SACHI | — |
| Art Unit | Apps |
|---|---|
| 1658 | 3 |
| 1734 | 1 |
| 1672 | 1 |
| 1621 | 1 |
| 1654 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18704949 | LUMINESCENT MATERIAL AND MINI-LED DEVICE PREPARED USING LUMINESCENT MATERIAL | GROOMS, NOA WILLIAM FRAN | 1734 | §103§112 | Non-Final OA | — | Pending | Apr 26, 2024 |
| 18292538 | GENERAL AFFINITY EPITOPE POLYPEPTIDE FOR HUMAN RHINOVIRUS, AND ANTIBODY AND USES THEREOF | WANG, RUIXUE | 1672 | §103§112 | Non-Final OA | — | Pending | Jan 26, 2024 |
| 18398278 | ANTIMICROBIAL PEPTIDE SCYAMPCIN44-63 AND APPLICATION THEREOF | VARADARAJ, ARCHANA | 1658 | §101§102§112 | Non-Final OA | — | Pending | Dec 28, 2023 |
| 18544186 | CATALYST, APPLICATION THEREOF, AND METHOD FOR PREPARING 2,5-FURANEDICARBOXYLIC ACID BY CATALYZING 5-HYDROMETHYLFURFURAL IN BASE-FREE CONDITION | AULAKH, CHARANJIT | 1621 | §112 | Final Rejection | — | Pending | Dec 18, 2023 |
| 18350803 | PEPTIDE DISINFECTANT FOR PREVENTING CORONAVIRUSES | NIEBAUER, RONALD T | 1658 | §101§102§112 | Non-Final OA | 60d | Pending | Jul 12, 2023 |
| 18337091 | PREPAKAGED POLYMERASE CHAIN REACTION (PCR) REAGENT FOR NUCLEIC ACID AMPLIFICATION AND METHOD THEREOF | REYNOLDS, FRED H | 1658 | §112 | Final Rejection | 70d | Pending | Jun 19, 2023 |
| 18005543 | CELL-PENETRATING PEPTIDE AND USE THEREOF | JAUHARI, SACHI | 1654 | §101§112 | Final Rejection | — | Pending | Jan 13, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial